@Article{Zhao2015,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
volume="19",
number="3",
year="2015",
title="MicroRNA-7 enhances cytotoxicity induced by gefitinib in non-small cell lung cancer via inhibiting the EGFR and IGF1R signalling pathways",
abstract="Gefitinib is a tyrosine kinase inhibitor that has been used for the treatment of non-small-cell lung carcinoma (NSCLC). The ability of miR-7 to enhance gefitinib-induced cytotoxicity in NSCLC cells was evaluated in this study. We found that miR-7 significantly decreased the IC50 of gefitinib and inhibited cell growth. G0/G1 cell cycle arrest and cell apoptosis were increased after the treatment of gefitinib coupled with miR-7 transfection. In addition, levels of Raf1, IGF1R, and PI3K and phosphorylation levels of Akt and ERK were also significantly decreased. Our results suggest that miR-7 may provide a novel therapeutic target for the treatment of NSCLCs.",
author="Zhao, Jun-gang
and Men, Wan-fu
and Tang, Jun",
pages="201--206",
doi="10.5114/wo.2015.52655",
url="http://dx.doi.org/10.5114/wo.2015.52655"
}